Want to see HK:2487 full AI Analyst Report?
Top Page
Cutia Therapeutics
(2487)
Select Model
Select Model
Rating:43Neutral
Price Target:
HK$1.50
▼(-67.32% Downside)
Action:Reiterated
Date:08/22/26
The score is held down primarily by weak financial fundamentals—large operating losses, net losses exceeding revenue, and continued negative free cash flow despite improved burn. Technicals add further downside risk, with the stock in a pronounced downtrend and bearish momentum readings. Valuation provides limited support because the negative P/E reflects unprofitability and no dividend yield is available.
Positive Factors
Revenue Growth
The sharp acceleration in revenue growth indicates stronger commercial traction and improving demand for the dermatology business. If sustained, a larger revenue base can improve operating leverage, support continued investment, and provide a stronger foundation for eventual profitability.
Negative Factors
Deep Operating Losses
Losses remain exceptionally large relative to revenue, showing that the company is still far from break-even. This weak profitability limits internally generated funding, makes future earnings highly dependent on successful scaling, and leaves results vulnerable if revenue growth slows.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The sharp acceleration in revenue growth indicates stronger commercial traction and improving demand for the dermatology business. If sustained, a larger revenue base can improve operating leverage, support continued investment, and provide a stronger foundation for eventual profitability.
Read all positive factors
Cutia Therapeutics (2487) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$612.36M
Dividend YieldN/A
Average Volume (3M)93.97K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth35.47%
EPS Growth46.42%
CountryHK
Employees304
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.05
Shares Outstanding374,533,900
10 Day Avg. Volume112,580
30 Day Avg. Volume93,966
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.52
Price to Sales (P/S)4.01
P/FCF Ratio-4.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)HK$580.00M
Cutia Therapeutics Business Overview & Revenue Model
Company Description
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, ...
Cutia Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 336.15M | 279.62M | 137.62M | 11.37M | 2.04M |
| Gross Profit | 195.79M | 143.46M | 71.01M | 7.94M | 1.61M |
| EBITDA | -277.93M | -430.69M | -1.92B | -535.19M | -309.23M |
| Net Income | -340.19M | -433.81M | -1.96B | -555.84M | -319.58M |
Balance Sheet | |||||
| Total Assets | 1.31B | 1.39B | 1.71B | 1.45B | 1.49B |
| Cash, Cash Equivalents and Short-Term Investments | 789.16M | 876.15M | 1.27B | 1.08B | 1.38B |
| Total Debt | 317.53M | 320.94M | 243.75M | 54.13M | 26.53M |
| Total Liabilities | 405.08M | 418.51M | 357.76M | 2.69B | 2.29B |
| Stockholders Equity | 885.66M | 974.73M | 1.35B | -1.25B | -790.51M |
Cash Flow | |||||
| Free Cash Flow | -302.97M | -468.66M | -437.23M | -371.50M | -185.76M |
| Operating Cash Flow | -290.09M | -442.98M | -381.31M | -236.19M | -159.88M |
| Investing Cash Flow | -20.28M | 316.07M | -203.58M | 462.06M | -410.65M |
| Financing Cash Flow | 193.03M | 37.84M | 588.32M | -10.25M | 480.76M |
Cutia Therapeutics Technical Analysis
Negative
4.59
Price Trends
2.28
Negative
3.06
Negative
4.10
Negative
Market Momentum
-0.20
Positive
22.91
Positive
14.30
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2487, the sentiment is Negative. The current price of 4.59 is above the 20-day moving average (MA) of 1.91, above the 50-day MA of 2.28, and above the 200-day MA of 4.10, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 22.91 is Positive, neither overbought nor oversold. The STOCH value of 14.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2487.
Cutia Therapeutics Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | HK$833.54M | -2.16 | -66.16% | ― | 67.48% | 43.84% | |
50 Neutral | HK$1.96B | 18.79 | 48.25% | ― | 88.38% | ― | |
46 Neutral | HK$1.54B | -6.98 | -41.81% | ― | ― | -4.24% | |
43 Neutral | HK$612.36M | -1.73 | -35.24% | ― | 35.47% | 46.42% | |
43 Neutral | HK$436.45M | -1.52 | -32.08% | ― | 215.14% | 40.49% | |
42 Neutral | HK$423.95M | -4.51 | 133.13% | ― | -100.00% | 30.94% |
* General Sector Average
HK:2487
Cutia Therapeutics
1.60
-9.14
-85.10%
HK:2126
JW (Cayman) Therapeutics Co. Ltd.
2.02
-3.08
-60.39%
HK:2181
Mabpharm Limited
0.45
-0.33
-42.31%
HK:2257
Sirnaomics Ltd.
3.86
-14.93
-79.47%
HK:3681
SinoMab Bioscience Ltd.
1.08
-0.81
-42.86%
HK:6628
Transcenta Holding Limited
0.85
-3.97
-82.37%
Cutia Therapeutics Corporate Events
Cutia Therapeutics’ Botulinum Toxin CU-20101 BLA Accepted by China’s NMPA
Sep 2, 2026
Cutia Therapeutics has announced that China’s National Medical Products Administration has accepted its Biologics License Application for CU-20101, a botulinum toxin type A injection targeting moderate to severe glabellar lines. The product ...
Cutia Therapeutics Accelerates Commercial Push in China’s Dermatology Market
Aug 31, 2026
Cutia Therapeutics reported solid progress in its interim business update for the six months to 30 June 2026, highlighting rapid commercialization of its flagship dermatology drugs. Since their launch in late October 2025, Finjuve and Amzeeq have ...
Cutia Therapeutics Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 19, 2026
Cutia Therapeutics has scheduled a board meeting for 31 August 2026 to review and approve the interim results for the six months ended 30 June 2026 and to authorize their publication. The board will also consider whether to recommend an interim di...
Cutia Therapeutics Wins Shareholder Backing for All AGM Resolutions
Jun 26, 2026
Cutia Therapeutics secured shareholder approval for all resolutions at its 26 June 2026 annual general meeting, including adoption of the 2025 audited financial statements and the re-election of several non-executive and independent non-executive ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.